By Fineline Cube 
China-based MicroPort NeuroTech Limited (HKG: 2172) announced that its NUMEN Nest, an enhanced version of its NUMEN detachable embolization coil family, has secured marketing approval from the US Food and Drug Administration (FDA).
Product Innovation
NUMEN Nest is designed to address the challenges of treating aneurysms with its superior adaptability to irregular aneurysm morphology. The product maintains structural stability while offering two series with 130 specifications. This extensive range covers various diameter and length requirements, making it a versatile tool for clinicians.
Technical Advancements
The upgraded NUMEN Nest optimizes the primary helix outer diameter, enhancing embolization efficiency and softness. These improvements reduce procedure time and elevate clinical safety and efficacy, positioning it as a significant advancement in aneurysm treatment.-Fineline Info & Tech